trending Market Intelligence /marketintelligence/en/news-insights/trending/lzG9eCEt04zLgRdpRVrePA2 content esgSubNav
In This List

FSD Pharma receives approval to list on Nasdaq

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


FSD Pharma receives approval to list on Nasdaq

FSD Pharma Inc. received approval to list its shares on the Nasdaq Capital Market.

The Cobourg, Ontario-based company will have its class B subordinate voting shares, a type of common stock, listed on Nasdaq. Trading of the stocks will start in the near future, the company said, without giving a date.

FSD Pharma is already listed on the Canadian Securities Exchange. The company in October said it is consolidating its class A multiple voting shares and its class B subordinate voting shares, each on a 1-to-201 basis. Following consolidation, FSD Pharma will have 72 issued and outstanding class A shares, representing 276,660 votes or about 72% of the company's voting rights.

FSD Pharma is a medical cannabis company focused on developing indoor-grown pharmaceutical-grade cannabis.